BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapyProactive Investors • 09/28/23
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatmentMarket Watch • 09/28/23
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALSPRNewsWire • 09/28/23
BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapyProactive Investors • 09/25/23
Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major RisksSeeking Alpha • 09/15/23
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 08/14/23
BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate UpdatePRNewsWire • 08/07/23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct OfferingPRNewsWire • 07/17/23
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development OfficerPRNewsWire • 07/12/23
BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of NeurodegenerationPRNewsWire • 07/07/23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee ChairPRNewsWire • 06/20/23
BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual ConferencePRNewsWire • 06/16/23
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023PRNewsWire • 06/06/23
BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development SummitPRNewsWire • 05/19/23
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 05/15/23
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate UpdatePRNewsWire • 05/09/23
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical OfficerPRNewsWire • 04/24/23